Biocure Technology Inc. (BICTF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.73: the stock has moved about 273% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiocure Technology Inc. (BICTF) trades at $0.01. Biocure Technology Inc. focuses on developing and commercializing biopharmaceutical technologies, including treatments for multiple sclerosis and macular degeneration. The company also researches CAR T Cell therapy and vaccines. Sector: Energy.
Price as of · Last analyzed: Jun 1, 2026Analyst Coverage for BICTF: BICTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Biocure Technology Inc. (BICTF) Energy Operations & Outlook
Biocure Technology Inc., a biotechnology company based in Canada, develops and commercializes biopharmaceutical technologies, including treatments for multiple sclerosis and macular degeneration. The company's pipeline also includes CAR T-cell therapy and vaccines, positioning it within the competitive healthcare landscape focused on innovative therapies.
What Is the Investment Thesis for BICTF?
Biocure Technology Inc. presents a high-risk, high-reward investment profile given its focus on early-stage biopharmaceutical development. The company's pipeline, including treatments for multiple sclerosis, macular degeneration, and neutropenia, addresses significant market needs. A key value driver is the potential success of its CAR T Cell therapy research, which could provide substantial returns if clinical trials are successful. However, the company's OTC listing and limited financial information increase the risk profile. Upcoming catalysts include the progression of its drug candidates through clinical trials and potential partnerships for commercialization. The company's beta of 3.73 indicates high volatility relative to the market. Investors should carefully consider the risks associated with early-stage biotechnology companies before investing.
Based on FMP financials and quantitative analysis
BICTF Key Highlights
Focus on developing Interferons-ß for multiple sclerosis treatment.
- Development of Ranibizumab, a monoclonal antibody fragment for macular degeneration.
- Research and development of CAR T Cell therapy for cancer treatment.
- Engaged in developing Filgrastim to treat neutropenia.
- The company was founded in 2005 and is headquartered in Vancouver, Canada.
Who Are BICTF's Competitors?
BICTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| JAGU Jaguar Uranium Corp. Class A | $0.76 | -7.20% | $15.4M | 42 5-pillar |
| NUCL Eagle Nuclear Energy Corp. | $2.98 | -3.56% | $88.5M | 40 5-pillar |
| EU enCore Energy Corp. | $0.47 | -1.54% | $92.9M | — |
| URG Ur-Energy Inc. | $0.51 | -6.32% | $202M | — |
| ISOU IsoEnergy Ltd. | $6.42 | -3.02% | $422M | 52 5-pillar |
| UROY Uranium Royalty Corp. | $2.60 | -0.38% | $991M | 44 5-pillar |
| UUUU Energy Fuels Inc. | $5.64 | -4.89% | $1.49B | — |
| DNN Denison Mines Corp. | $1.83 | -3.17% | $1.66B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BICTF's Key Strengths?
Diverse pipeline of biopharmaceutical products.
- Focus on innovative therapies.
- Research and development capabilities.
- Potential for strategic partnerships.
What Are BICTF's Weaknesses?
Early-stage development of products.
- Limited financial resources.
- Dependence on research and development success.
- OTC market listing.
What Could Drive BICTF Stock Higher?
Clinical trial results for Interferons-ß in multiple sclerosis treatment.
- Clinical trial results for Ranibizumab in macular degeneration treatment.
- Progress in CAR T Cell therapy research and development.
- Potential partnerships for commercialization of products.
- Development of foot and mouth disease vaccine.
What Are the Key Risks for BICTF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Funding challenges.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for BICTF?
- Biocure's research in this area represents a significant growth opportunity. Successful development and commercialization of a CAR T-cell therapy product could generate substantial revenue and establish Biocure as a key player in the oncology market. The timeline for this opportunity depends on the progress of clinical trials and regulatory approvals, with potential for initial market entry within the next 5-7 years.
- Expansion of Ranibizumab Applications: Ranibizumab is currently used to treat macular degeneration, but ongoing research suggests it may have applications for other ophthalmic conditions. Expanding the indications for Ranibizumab could significantly increase its market potential. The global market for macular degeneration treatments is substantial, and Biocure could capture a larger share by demonstrating the efficacy of Ranibizumab in treating additional eye disorders. This expansion could occur within the next 3-5 years, pending clinical trial results and regulatory approvals.
- Commercialization of Interferons-ß for Multiple Sclerosis: The market for multiple sclerosis treatments is substantial, with a growing demand for effective therapies. Biocure's development of Interferons-ß represents a significant opportunity to address this market need. Successful commercialization of Interferons-ß could generate substantial revenue and establish Biocure as a key player in the MS treatment landscape. The timeline for this opportunity depends on the progress of clinical trials and regulatory approvals, with potential for market entry within the next 5-7 years.
- Development of Foot and Mouth Disease Vaccine: The global market for veterinary vaccines is growing, driven by increasing concerns about animal health and food safety. Biocure's research into a foot and mouth disease vaccine represents a diversification opportunity with potential for significant returns. Successful development and commercialization of this vaccine could generate revenue from both government and private sector clients. This opportunity could materialize within the next 3-5 years, depending on research progress and regulatory approvals.
- Hair Growth Product Development: The market for hair growth products is substantial, driven by increasing concerns about hair loss and thinning. Biocure's research in this area represents a diversification opportunity with potential for significant returns. Successful development and commercialization of a hair growth product could generate revenue from both consumer and professional markets. This opportunity could materialize within the next 2-4 years, depending on research progress and regulatory approvals.
What Opportunities Does BICTF Have?
- Expansion of product pipeline.
- Strategic partnerships with larger pharmaceutical companies.
- Successful commercialization of new therapies.
- Growth in the biotechnology market.
What Are BICTF's Competitive Advantages?
- Proprietary biopharmaceutical technologies.
- Research and development expertise.
- Intellectual property protection through patents.
- Potential for strategic partnerships with larger pharmaceutical companies.
What Does BICTF Do?
Founded in 2005 and headquartered in Vancouver, Canada, Biocure Technology Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative therapies. The company's primary focus is on recombinant and ranibizumab-based biopharmaceutical technologies. Its product pipeline includes Interferons-ß for the treatment of multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. Biocure is also developing Ranibizumab, a monoclonal antibody fragment, for treating macular degeneration and macular edema, significant causes of vision loss. Additionally, the company is working on Filgrastim to treat neutropenia, a condition characterized by a deficiency of white blood cells often caused by cancer treatments. Beyond these core areas, Biocure is involved in research and development of CAR T Cell therapy, a promising approach to cancer treatment that involves modifying a patient's own immune cells to target and destroy cancer cells. The company is also exploring the development of a foot and mouth disease vaccine and hair growth products, diversifying its research portfolio. Biocure operates primarily through its subsidiary, focusing on bringing novel biopharmaceutical technologies to market.
What Products and Services Does BICTF Offer?
- Develop Interferons-ß for the treatment of multiple sclerosis.
- Develop Ranibizumab, a monoclonal antibody fragment for macular degeneration.
- Research and develop CAR T Cell therapy for cancer treatment.
- Develop Filgrastim to treat neutropenia.
- Research and develop a foot and mouth disease vaccine.
- Research and develop hair growth products.
How Does BICTF Make Money?
- Develop and license biopharmaceutical technologies.
- Conduct research and development to create new therapies.
- Seek partnerships for commercialization of products.
- Generate revenue through licensing agreements and product sales.
What Industry Does BICTF Operate In?
Biocure Technology Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. Biocure's focus on recombinant and ranibizumab technologies places it in a competitive landscape with both established pharmaceutical companies and smaller biotech firms. The success of Biocure depends on its ability to navigate the complex regulatory environment, secure funding for research and development, and successfully commercialize its products.
Who Are BICTF's Key Customers?
- Pharmaceutical companies seeking to license new therapies.
- Healthcare providers prescribing treatments for multiple sclerosis, macular degeneration, and neutropenia.
- Patients receiving CAR T Cell therapy for cancer treatment.
- Government agencies and veterinary clinics purchasing vaccines.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Biocure Technology Inc. operates in the Energy sector. It is headquartered in Vancouver, Canada.
Key Financial Metrics
Its free cash flow yield is -9.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Biocure Technology Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BICTF Financials
Bull Case vs Bear Case
Bull Case
- Diverse pipeline of biopharmaceutical products.
- Focus on innovative therapies.
- Research and development capabilities.
- Potential for strategic partnerships.
Bear Case
- Early-stage development of products.
- Limited financial resources.
- Dependence on research and development success.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
BICTF Latest News
No recent news available for BICTF.
BICTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BICTF.
Price Targets
Wall Street price target analysis for BICTF.
BICTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BICTF; grades run from A+ (80-100) to F (below 30).
Leadership: Yee Sing Cheng
CEO
Yee Sing Cheng serves as the Chief Executive Officer of Biocure Technology Inc. Therefore, a comprehensive biography cannot be constructed at this time. Further research would be required to provide a more detailed profile.
Track Record: Information regarding Yee Sing Cheng's track record, including key achievements, strategic decisions, and company milestones under their leadership, is not available in the provided source data. Therefore, a comprehensive assessment of their performance cannot be provided at this time. Further research would be required to provide a more detailed analysis.
BICTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biocure Technology Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing requirements or SEC reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Uncertainty regarding the company's financial health.
- Verify the company's legal status and registration.
- Attempt to obtain audited financial statements.
- Assess the company's management team and their experience.
- Evaluate the company's business plan and prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Research the company's history and any potential red flags.
- Company has been in operation since 2005.
- Focus on developing biopharmaceutical technologies.
- Presence of a CEO (Yee Sing Cheng).
Common Questions About BICTF (Energy)
Is BICTF a good stock to buy?
Stock Expert AI does not rate BICTF buy, sell or hold. Biocure Technology Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BICTF stock price today?
The last price recorded on this page for Biocure Technology Inc. (BICTF) is $0.01, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about BICTF stock?
As of June 1, 2026, there is no available analyst coverage or consensus rating for Biocure Technology Inc. (BICTF). This is likely due to the company's listing on the OTC market and its limited financial disclosure.
What are the key factors to evaluate for BICTF?
Evaluate BICTF on fundamentals, analyst consensus, and risk factors. A key value driver is the potential success of its CAR T Cell therapy research, which could provide substantial returns if clinical trials are successful. Not financial advice.
How frequently does BICTF data refresh on this page?
BICTF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BICTF's recent stock price performance?
Biocure Technology Inc. (BICTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of biopharmaceutical products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BICTF overvalued or undervalued right now?
Biocure Technology Inc. (BICTF) is loss-making, so its trailing P/E is negative (-2.57x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BICTF before investing?
Before investing in Biocure Technology Inc. (BICTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited financial information available for Biocure Technology Inc.
- OTC market listing increases investment risk.
- Analyst coverage is not available.